52 results about "Clostridium difficile" patented technology

Compositions comprising aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and / or isolating Clostridium difficile spores is provided.

Provided is a growth inhibitor for Clostridioides difficile. A growth inhibitor for Clostridioides difficile, comprising killed Enterococcus faecalis. Also provided are a parenteral pharmaceutical preparation, a bactericide, a disinfectant, an antibacterial agent, a sanitizer or a detergent for inhibiting the growth of Clostridioides difficile.

The present application belongs to the technical field of bacterial detection, and particularly relates to a Clostridium difficile multi-locus genotyping detection kit and application thereof. The present application aims to provide a new method to directly type a main Clostridium difficile strain sequence type (ST). The technical scheme of the present application is a multiplex fluorescence PCR primer set and probe for Clostridium difficile multi-locus genotyping detection, wherein the primer and probe are shown in Seq ID No. 1-18. The present application discloses a multiplex fluorescence PCR reagent for 7 main ST types of Clostridium difficile based on a fluorescence PCR-dissolution curve method. The reagent can simultaneously detect 7 main ST types of Clostridium difficile in the same PCR reaction system.

The present invention discloses an antibody against Clostridium difficile specific protein, a magnetic bead-antibody conjugate and its application. The monoclonal antibody is any one of monoclonal antibody CD1, monoclonal antibody CD2, monoclonal antibody CD3 and monoclonal antibody CD4. The magnetic bead-antibody conjugate is formed by conjugating a monoclonal antibody with activated carboxyl magnetic beads to obtain the magnetic bead-antibody conjugate. Based on the magnetic bead-antibody conjugate sorting method, antibody magnetic beads that couple and recognize the Clostridium difficile secreted proteins TcdA, TcdB, the highly expressed GDH on the surface of Clostridium difficile, and the LPxTG of Clostridium difficile are used to capture Clostridium difficile, achieving the purpose of rapidly isolating Clostridium difficile from fecal samples. The present invention is based on the immunomagnetic bead separation technology of antigen-antibody reaction for separation, with the characteristics of being rapid, simple, having high enrichment efficiency and strong specificity. The present invention can be used to isolate and remove Clostridium difficile in fecal microbiota transplantation, and can also be used for strain identification and sequencing.

The present application relates to methods of treating or preventing infection-related immune conditions using compositions comprising IgM. In particular, the present application provides a method for treating immune complications resulting from infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. In some embodiments, the treatment of immune complications is carried out by immunomodulation. Also provided is a method for immunomodulating an infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. The present application also provides a composition comprising IgM for use in the treatment of sepsis and a composition comprising IgM for use in the treatment of immune complications resulting from infection. In some embodiments, the above-mentioned infection or sepsis results from E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum, or a combination thereof.

The invention discloses a primer group for simultaneously detecting four equine digestive tract bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-8, and the four equine digestive tract bacteria are salmonella enteritidis, salmonella typhimurium, clostridium difficile and lawsonia intracellular. Extracting total DNA (deoxyribonucleic acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; the total DNA is used as a template, and the primer group is used for multiple PCR reaction to obtain an amplification curve. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.

To provide: an antimicrobial composition containing hydrogen peroxide that has increased efficacy against microorganisms and has no unpleasant odor; a wiping product; a method for disinfecting a hard surface; and an antimicrobial composition precursor.SOLUTION: An antimicrobial composition comprises: a hydrogen peroxide source; and a peroxide adjuvant, the peroxide adjuvant comprising an organic acid and / or salt thereof having a pKa from about 1 to about 6, the antimicrobial composition being free of acetic acid. The peroxide adjuvant is present in the composition in an amount sufficient for the composition to achieve at least 3 log10 reduction after a three minute contact time when tested against Clostridium difficile according to ASTM Test Methods E2197-11 and E2839-11.SELECTED DRAWING: Figure 1

This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and / or toxin B.

The present invention provides isolated Clostridium difficile binary toxin antibodies that are capable of neutralizing binary toxin with high potency, polypeptides and nucleic acids encoding the same, and methods of use thereof.

Provided herein are compositions to treat Clostridioides difficile (C. difficile), Mycobacterium tuberculosis (M. tuberculosis) and Enterococcus faecalis (E. faecalis). These compositions are related to the known compounds (+)-Puupehenone and (+)-ent-Chromazonarol, which are both naturally occurring products. The new compositions were shown to potently inhibit both growth and toxin production of C. difficile as well as inhibit the growth and survival of both replicating and dormant M. tuberculosis. In the United States the C. difficile burden is approximately 453,000 hospital cases and 29,000 deaths annually. Globally, about 10 million people fall ill from tuberculosis and 1.4 million died from the disease. In addition, the known compound (+)-ent-Chromazonarol (10) was found for the first time to strongly inhibit the growth of E. faecalis. E. faecalis has grown drug resistant to vancomycin. In 2017, Vancomycin-Resistant Enterococci (VRE) caused an estimated 54,500 infections among hospitalized patients and 5,400 estimated deaths in the United States.

Compositions comprising aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and / or isolating Clostridium difficile spores is provided.

A method for the treatment of one or more toxins in a subject is provided, the method comprising administering to the subject a therapeutically effective amount of a serine protease that enzymatically cleaves a specific toxin. Also provided is a method for preventing the progression of disease in a subject infected with Clostridioides difficile (CD), diarrhea, or infectious colitis, the method comprising administering to the subject a therapeutically effective amount of the protease. The protease retains its activity up to 65°C. Treatment with the protease in mice infected with CD provided a 10-fold survival benefit compared to CD-infected untreated mice. TIFF2025521857000010.tif62147

The invention discloses an intestinal flora marker related to a children inflammatory bowel disease, a product and application of the intestinal flora marker. The intestinal flora marker disclosed by the invention is one or more of streptococcus salivarius, bacteroides ovatus, bacteroides vulgaris, clostridium altaicum, actinomycetes decayed tooth and clostridium difficile, and can be applied to prediction and diagnosis of patients with the inflammatory bowel disease in children, the diagnosis process is completely noninvasive, and the accuracy is high.

Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and / or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.

The present invention relates to the application of creatmycin in inhibiting gastrointestinal tract pathogenic bacteria, and the gastrointestinal tract pathogenic bacteria include but are not limited to: Helicobacter pylori, Clostridium difficile, Bacteroides fragilis, Escherichia fergusonii, Clostridium sporogenes.

The invention provides a non-protein metabolite of Thailand enterococcus d5B and application of the non-protein metabolite. The non-protein metabolite of the Thailand enterococcus d5B is a product obtained after enzymolysis of cell-free supernate of the Thailand enterococcus d5B by protease; the collection number of Thailand enterococcus d5B is CCTCC (China Center for Type Culture Collection) NO: M 20232279, and the Thailand enterococcus d5B is collected in the China Center for Type Culture Collection on November 20, 2023. The inventor discovers that the non-protein metabolite of the Thailand enterococcus d5B can play a role in killing clostridium difficile in a concentration-dependent manner, a good antibacterial effect can be achieved when the concentration of CFS containing the non-protein metabolite is 1 mu g / mu L or above, and the CFS containing the non-protein metabolite is an effective clostridium difficile bacteriostatic active component; the non-protein metabolite of the Thailand enterococcus has the antibacterial effect on the clostridium difficile for the first time at home and abroad, and has extremely high application value in the aspect of clinical treatment.

This invention discloses the Clostridium difficile phage recombinant lyase Lys51, its preparation method, and its application, relating to the field of genetic engineering technology. The invention involves introducing the recombinant plasmid pET-28a-SUMO-Lys51 into Escherichia coli BL21(DE3) competent cells via heat shock transformation; screening to obtain the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51; constructing the recombinant plasmid pET-28a-SUMO-Lys51 and the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, further inducing the expression of Clostridium difficile phage recombinant lyase Lys51 in the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, and then purifying it to achieve the complete process for preparing Clostridium difficile phage recombinant lyase Lys51.

The invention discloses a camel source single-domain antibody CB3 for recognizing linear B cell epitope in clostridium difficile methylase CamA and application of the camel source single-domain antibody CB3. The nucleotide sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 2. The camel source single-domain antibody CB3 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody CB3 can be used for detecting recombinant expressed CD-CamA and endogenous CD-CamA by methods such as enzyme-linked immunosorbent assay (ELISA) and western blot hybridization (WB).

A method of manufacturing ostrich antibodies may include immunizing mature female ostriches with a mixture solution comprising Clostridium difficile toxin A and toxin B, obtaining eggs from the immunized ostriches, and purifying egg yolk antibodies from the eggs.

This invention discloses a trace element composition and its application for improving the fermentation efficiency of *Clostridium autoethanogenum* under conditions containing CO2 and H2 syngas, belonging to the field of microbial fermentation technology. The trace element composition comprises the following components: 1.5% nitroglycerin, 3% magnesium sulfate, 0.5% manganese sulfate, 0.1% ferrous sulfate, 0.18% cobalt sulfate, 0.1% calcium chloride, 0.18% zinc sulfate, 0.01% copper sulfate, 0.02% potassium aluminum sulfate, 0.01% boric acid, 0.01% sodium molybdate, 0.03% nickel chloride, and 0.004% sodium tungstate. Using the trace element composition of this invention, after 4 days of fermentation under conditions containing CO2 and H2 syngas (CO2:H2=1:2, CO-free), the cell concentration is nearly twice that of the control group without the composition, and the syngas utilization rate is significantly improved. This invention provides an effective technical solution to the problem of low fermentation efficiency of self-producing ethanol Clostridium in a pure CO2 and H2 system, and has good prospects for industrial application.

The invention belongs to the technical field of pathogenic bacterium detection, and particularly discloses a diluent for detecting clostridium difficile in an excrement sample and application of the diluent. The diluent for detecting the clostridium difficile in the excrement sample is prepared from fetal calf serum, bovine serum albumin, a detergent and an anti-interference agent according to a specific proportion. Wherein efficient extraction and detection of the clostridium difficile GDH are realized through broad-spectrum protection of the FBS, directional stabilization of the BSA, formation of a multi-layer protection network through the FBS-BSA, targeted splitting decomposition of the detergent and specific removal of the anti-interference agent. According to the invention, the relation among the splitting efficiency, enzyme protection and interference elimination is balanced by precisely regulating and controlling the proportion of the related components, and a reliable technical scheme is provided for clinical rapid diagnosis of clostridium difficile. The kit provided based on the diluent has the advantages of being good in stability, high in accuracy, low in cost, convenient to use and the like, and the clostridium difficile in an excrement sample can be efficiently and rapidly detected by adopting the kit.

A disinfectant includes a source of chlorine, a buffer system, a pH adjuster, and a polar carrier. The disinfectant has a pH of 9.9-11 and activity against Clostridium difficile spores and Mycobacterium within a 3 minute kill time. In one embodiment, the disinfectant includes sodium hypochlorite as a source of chlorine, a carbonate or phosphate buffer system, a hydroxide pH adjuster, and a polar carrier, wherein the disinfectant has a pH of 10.0-10.5 and kills at least 90% of Clostridium difficile spores and Mycobacterium within a 3 minute kill time.

The present invention relates to the field of molecular biology detection technology, and specifically to a probe cluster, a kit and its application in detecting Clostridium difficile, wherein the kit includes a recombinase-mediated isothermal nucleic acid amplification system, amplification primers of the conservative sequence of the toxin B gene of Clostridium difficile, four sets of locked nucleic acid-modified G-quadruplex / heme DNA enzyme probes and competitive probes. In this method, nucleic acid amplification and its hybridization with the probe are carried out under constant temperature (42°C-45°C), and there is no need to purify the amplified product, and the steps are few and the speed is fast, and all detections can be completed within 40 minutes. The method has high sensitivity, good specificity, does not rely on complex instruments, and the results can be directly observed with the naked eye, which is suitable for the rapid detection of Clostridium difficile.

The invention discloses a digital PCR (Polymerase Chain Reaction) joint detection method for four virulence related genes (tcdA, tcdB, tcdC and cdtB) of clostridium difficile and a kit thereof. The detection system comprises a specific primer pair as shown in SEQ ID NO: 1-13 and a fluorescence labeling probe group. Through a digital PCR technology platform, multi-target and high-sensitivity absolute quantitative detection is realized, interference of inhibitors in a sample can be effectively overcome, detection is completed within 4 hours, accurate pathogen load information is provided for clinic, and rapid diagnosis and treatment evaluation are assisted.

An immunogenic composition comprising a deletion mutant of a Clostridioides difficile TcdB toxin (such as TcdB2 or TcdB1) that lacks residues at least from amino acid residue 1769 to amino acid residue 1787 of a wild-type TcdB amino acid sequence or of a protein having high identity thereto, a vaccine comprising the immunogenic composition, a method of stimulating an immune response, a nucleic acid which encodes the amino acid sequence of the deletion mutant, a vector encoding the nucleic acid, and a host cell comprising the vector.

The present application firstly provides a cell wall anchor protein truncated Cwp66 which significantly improves the expression efficiency of exogenous proteins while retaining the cell wall anchoring function, resulting in unexpected technical effects. On this basis, the present application provides a cell wall protein display system which, when the bottom strain is non-toxic Clostridium difficile, exhibits excellent expression performance and colonization ability in the intestinal anaerobic environment, significantly better than the prior art. Further, the present application also provides a cell surface display system with non-toxic Clostridium difficile as the bottom strain, a recombinant strain displaying effector proteins on the cell wall surface; and its application in anti-tumor. The engineering strain not only realizes the efficient expression and display of effector proteins on the cell wall surface of Clostridium difficile, but also has excellent expression performance and colonization ability in the intestinal anaerobic environment, and can significantly inhibit the growth of tumors in a mouse model, providing a new idea for the treatment of colorectal cancer, and having important social significance and market value.

The invention provides a Bifidobacterium pseudocatenatum (Bifidobacterium pseudocatenatum) strain B24790 with the functions of inhibiting clinical multi-drug-resistant bacteria and resisting inflammation and application of the Bifidobacterium pseudocatenatum strain B24790, and belongs to the technical field of functional microorganisms. The invention discloses a bifidobacterium pseudocatenum strain B24790, and the preservation number of the bifidobacterium pseudocatenum strain B24790 is GDMCC No: 65515. The strain B24790 has good bacteriostatic activity on clinical multi-drug-resistant pathogenic bacteria such as clostridium difficile, acinetobacter baumannii HRAB-85, drug-resistant staphylococcus aureus, drug-resistant escherichia coli and pseudomonas aeruginosa PAO1, and also has a good anti-inflammatory effect. The strain B24790 is human-derived, has good gastrointestinal fluid resistance, and has the potential of colonization of human bodies. The bifidobacterium pseudocatenum strain B24790 provided by the invention has certain advantages in the aspects of drug-resistant bacterium infection and inflammatory diseases, can be used for preparing related products, and has a wide market prospect.

The invention provides a cascade amplification method based on Zn < 2 + > doped WOX nano-enzyme and application of the cascade amplification method in clostridium difficile toxin B detection, and relates to the technical field of lateral flow immunoassay. The cascade amplification method comprises the following steps that firstly, Zn / WOX at Au with reductase-like activity is subjected to immunochromatography to generate an initial colorimetric signal; and Zn / WOX (at) Au (at) Pt with peroxidase-like activity is formed through in-situ light-induced deposition of Pt to amplify a colorimetric signal, and then enzymatic color development is performed, so that the technical problem that clostridium difficile toxin B is difficult to quickly and highly sensitively detect in the prior art is solved, the colorimetric signal is remarkably enhanced while the simplicity and convenience of LFIA operation are maintained, and the detection sensitivity of clostridium difficile toxin B is improved. The technical effect of high-sensitivity colorimetric LFIA detection is realized.

A bio-sensor device for the electrochemical detection of a bacterial pathogen, the device including a sample chamber and an electronic data module. The sample chamber includes passive sensing probes to detect pathogenic antigens in a sample containing the bacterial pathogen. The probes detect a reaction voltage corresponding to an antigen-antibody reaction occurring when the pathogenic antigens come into contact with an antibody specific for pathogenic antigens present in in the contents of the sample chamber and contacted by the electrical probes. The electronic data module detects and processes electrical signals detected by the conductive electrical probes corresponding to an amount of the antigen present in the sample, wherein the reaction voltage is detected at the time of the reaction.